Favustat
Reading File
Searching the Web
Favustat drug
Finding Sources
"Favustat" isn't a recognized drug name in the medical literature or textbooks I checked - it doesn't appear in PubMed, drug databases, or rheumatology/pharmacology textbooks.
It's almost certainly a misspelling of Febuxostat, a xanthine oxidase inhibitor used to lower uric acid levels. Key facts:
- Class: Xanthine oxidase (XO) inhibitor, structurally unlike allopurinol (non-purine backbone) - Rheumatology, 2-Volume Set (2022, Elsevier)
- Use: Chronic management of hyperuricemia/gout in patients with an inadequate response to a maximally titrated dose of allopurinol, who are intolerant to allopurinol, or for whom allopurinol isn't advisable
- Mechanism: Potently and specifically inhibits xanthine oxidase, reducing uric acid production - Firestein & Kelley's Textbook of Rheumatology
- Important safety signal: The CARES trial found febuxostat carries a higher risk of cardiovascular death compared to allopurinol in patients with gout and existing cardiovascular disease, which led to an FDA boxed warning - Firestein & Kelley's Textbook of Rheumatology, p. Toxicity section
- Drug interactions: Increases plasma levels of drugs metabolized by xanthine oxidase (e.g., mercaptopurine, azathioprine) - concurrent use is contraindicated - Goodman & Gilman's Pharmacological Basis of Therapeutics
- Alternative use: Can be tried in patients with prior hypersensitivity reactions to allopurinol, though cross-reactivity is still possible - Katzung's Basic and Clinical Pharmacology
- Reserved for patients with contraindications to or intolerance of allopurinol, given its cardiovascular risk profile - Lippincott Illustrated Reviews Pharmacology
If you meant a different drug, or "Favustat" refers to something else (a supplement, a foreign brand name, or a different spelling entirely), let me know and I can look into it further.
This is a shared conversation. Sign in to Orris to start your own chat.